The last couple of months have witnessed the world in a state of virtual standstill. The SARS-CoV-2 virus has overtaken the globe to economic and social lockdown. Many patients with COVID-19 have compromised immunity, especially in an aged population suffering from Parkinson's disease (PD).

Alteration in dopaminergic neurons and deficiency of dopamine in PD patients are the most common symptoms affecting 1% population above the age of 60 years. The compromised immune system and inflammatory manifestation in PD patients make them an easy target. The most common drugs under trial for COVID-19 are remdesivir, favipiravir, chloroquine and hydroxychloroquine, azithromycin along with adjunct drugs like amantadine with some monoclonal antibodies.

Presently, clinically US FDA approved drugs in PD include Levodopa, catechol-O-methyl transferase (COMT) inhibitors, (Entacapone and Tolcapone), dopamine agonists (Bromocriptine, Ropinirole, Pramipexole, and Rotigotine), monoamine oxidase B (MAO-B) inhibitors (Selegiline and Rasagiline), amantadine and antimuscarinic drugs. The drugs have established mechanisms of action on PD patients with known pharmacodynamics and pharmacokinetic properties along with dose and adverse effects.

Conclusion and relevance of this review focus on the drugs that can be tried on PD patients with SAR CoV-2 infection, in particular, amantadine that has been approved by all the developed countries as a common drug possessing both antiviral properties by downregulation of CTSL, lysosomal pathway disturbance and change in pH necessary to uncoat the viral proteins and anti- Parkinson properties. To deal with the significant prognostic adverse effect of SARS-CoV-2 on PD, the present-day treatment options, clinical presentation and various mechanisms are the need of the hour.

在过去的几个月中，世界目睹了虚拟的停滞状态。SARS-CoV-2病毒已在全球范围内超过了经济和社会封锁的范围。许多COVID-19患者的免疫力受到损害，尤其是在患有帕金森氏病（PD）的老年人群中。

PD患者的多巴胺能神经元改变和多巴胺缺乏是最常见的症状，影响60岁以上人口的1％。PD患者的免疫系统受损和炎症表现使其容易成为目标。针对COVID-19进行试验的最常见药物是瑞姆昔韦，favipiravir，氯喹和羟氯喹，阿奇霉素以及诸如金刚烷胺等辅助药物和一些单克隆抗体。

目前，临床上美国FDA批准的PD药物包括左旋多巴，儿茶酚-O-甲基转移酶（COMT）抑制剂，（恩他卡朋和托卡朋），多巴胺激动剂（溴西汀，罗匹尼罗，普拉克索和罗替戈汀），单胺氧化酶B（MAO-B）抑制剂（司来吉兰和雷沙吉兰），金刚烷胺和抗毒蕈碱药物。该药物对具有已知药效学和药代动力学特性以及剂量和不良反应的PD患者建立了作用机制。

这篇评论的结论和相关性着重于可用于SAR CoV-2感染的PD患者的药物，尤其是金刚烷胺，该药物已被所有发达国家批准为通过CTSL下调而同时具有抗病毒特性的共同药物，溶酶体途径紊乱和pH值的变化是解开病毒蛋白和抗帕金森特性所必需的。为了应对SARS-CoV-2对PD的重大预后不良影响，目前需要时下的治疗选择，临床表现和各种机制。